Jackson Labs' Baddi drug manufacturing licence restored after suspension

New Delhi: The Himachal Pradesh government has partially restored Jackson Laboratories' drug manufacturing licence of its Baddi unit, while denying permission for higher-risk manufacturing lines including sterile injectables pending re-inspection and verified compliance.

The unit's licence was cancelled in June after several women in Kota, Rajasthan, died allegedly due to spurious oxytocin injections supplied by the company's Punjab unit.

Manufacturing licence for the Punjab facility remains cancelled. According to the records accessed by ET, Baddi unit's permission for testosterone injection has been cancelled. Likewise, product permissions for etophylline and theophylline prolonged-release tablets stand cancelled.


Manufacturing of general category capsules, SVP dry and liquid, ophthalmic including ear drops and nasal drops, and beta lactam category SVP dry only, also remains halted till the firm submits compliance of the observations and this is verified through a joint inspection.

An appeal to restore the licence of Jackson Laboratories' Punjab facility is listed to be heard on August 14. The deaths of several women in Kota following Caesarean sections pointed to spurious oxytocin injections administered to these women.

Reports indicated that laboratory testing of the injections, which were manufactured by Jackson Laboratories, found them to contain no active oxytocin content. The Rajasthan government has attributed the deaths to multiple factors.